Activist investor Elliott Investment Management has taken a stake in medical device firm Dexcom Inc. and struck a settlement ...

Elliott did not disclose the size of its stake but described itself as one of Dexcom’s largest investors. The activist investor’s involvement comes as Dexcom prepares to present its strategic and ...

DexCom (NASDAQ:DXCM) stock saw a notable increase of 16% on Friday following the announcement of its Q1 earnings and a share buyback program. The company’s first-quarter sales hit $1.04 billion, ...

If you are wondering whether DexCom's current share price still reflects its potential, the recent valuation signals give you plenty to think about. The stock closed at US$61.14, with a gain of 2.8% ...

DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A strong fourth-quarter 2024 performance and a series of favorable coverage decisions are ...

DexCom (NASDAQ:DXCM) stock experienced a significant 16% surge on Friday following its Q1 earnings release and a share buyback announcement. The company’s first-quarter sales reached $1.04 billion, ...

Medical device company DexCom (NASDAQ:DXCM) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 15% year on year to $1.19 billion. The company expects the full year’s ...

Analysts feared the advent of GLP-1 medications would harm DexCom's blood glucose monitoring devices. However, as its turns out, DexCom's devices are being prescribed together with GLP-1s. The company ...

It's been a tough year for DexCom (NASDAQ: DXCM), whose stock price is down 25% since the start of 2025. It's a surprising performance, given that the overall stock market has been doing well; you ...